• Progression on uses of Real-World Data across the ecosystem
• Global regulatory perspective on Real-World Evidence Guidance- FDA & EMA
• Applications of Artificial Intelligence & Blockchain for Real-World Data Analysis
• Market Access and Pricing
• COVID-19 impact- Identifying and overcoming challenges in Real-World Evidence space

From pharmaceutical and Biopharmaceutical companies-

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologist, within the following departments

• Real-World Evidence
• Health Economics & Outcomes Research
• Patient Access
• Value Access
• Clinical Operations
• Clinical Development
• Center for Observational and Real-World Evidence  

• Understand the impact of innovative real-world evidence partnerships for better data
• To explore the capabilities of using Artificial Intelligence & Machine Learning for better Data Analysis
• Learn about global regulatory perspective on Real-World Evidence Guidance
• Learn about best practices for the commercial structure of drugs, from development to market access strategy
• Opportunity to network and exchange scientific knowledge with expert speakers from leading manufacturers, global regulators, and solution providers